- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00155181
Molecular Mechanism of Nasopharyngeal Carcinoma
the Garduate Institute of Microbiology in National Taiwan University
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
Nasopharyngeal carcinoma (NPC), a human malignancy derived from the nasopharyngeal epithelial cells, is occurring highly frequently in Taiwan. Of note, the average ages of NPC individuals are usually ten years younger than those of patients with other head and neck cancers. Clinically, this early onset and high incidence of metastasis in NPC may contribute to its poor prognosis. Fortunately, NPC is usually radio-and chemo-therapy sensitive during the early stage. So, the more we understand NPC pathogenesis, the more efficient detection methods would be developed for NPC early diagnosis and prognosis.
Four unique characteristics have been reported for NPC: geographic preference, heavy infiltration of lymphocytes, high incidence of metastasis and association with Epstein-Barr virus (EBV). According to our hypothesis that both cellular changes and viral factors are crucial for NPC development, four major long-term study goals have been carried out in our lab: (1) identification and characterization of the cellular and viral factors that are involved in NPC formation, (2) elucidation of potencies of these molecules as clinical diagnosis and prognosis markers of NPC, (3) investigation of the molecular and biological linkage between EBV infection and NPC development and (4) establishment of a drug-screening system for NPC chemotherapy.
Based on our assumption that both cellular genes and viral factors are involved in NPC carcinogenesis, the following genes are chosen as the major study targets in this five-year grant. Firstly, to asses the alteration of cellular gene expression, we choose three cytokine genes 【interleukin (IL)-1, IL-7 and IL-13】, three inhibitors of apoptosis proteins (IAP) genes (survivin, HIAP-1, and HIAP-2), two specific cellular genes (osteoblast-specific factor-2 and polymeric immunoglobulin receptor) and one tumor suppressor gene (tumor susceptibility gene TSG101) in our proposal. All these genes exhibit special expression profiles in NPC biopsies in our preliminary study. So, the regulation and effect of these genes in epithelial cells would be the study focus. Secondly, two EBV viral genes, Zta and LMP2A, the former encoded immediately early lytic product and the later encoded latent membrane protein, are selected for this study. In our previous grant, we found that Zta can up-regulate TKT (trk-related tyrosine kinase) and matrix metalloproteinases (MMP)-1 which is a down-stream effector of TKT. Therefore we will extend the study on how Zta and LMP2A regulate and influence anti-apoptotic network and metastasis progression. Based on our preliminary data, this proposal is highly approachable and the results may provide valuable information for NPC diagnosis, prognosis and treatment.
Studietyp
Inskrivning
Kontakter och platser
Studiekontakt
- Namn: Ching-Hwa Tsai, Ph D
- Telefonnummer: 8298 886-2-23123456
- E-post: chtsai@ha.mc.ntu.edu.tw
Studieorter
-
-
-
Taipei, Taiwan, 100
- Rekrytering
- National Taiwan University College of Medicine
-
Kontakt:
- Te-Huei Yeh, MD, Ph D
- Telefonnummer: 5223 886-2-23123456
- E-post: yth@ha.mc.ntu.edu.tw
-
Huvudutredare:
- Ching-Hwa Tsai, pH.D
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- diagnosis of nasopharyngeal carcinoma
Exclusion Criteria:
-
Studieplan
Hur är studien utformad?
Designdetaljer
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Studiestol: Ching-Hwa Tsai, Ph D, National Taiwan University College of Medicine
Studieavstämningsdatum
Studera stora datum
Studiestart
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter histologisk typ
- Neoplasmer
- Neoplasmer efter plats
- Neoplasmer, körtel och epitel
- Faryngeala neoplasmer
- Otorhinolaryngologiska neoplasmer
- Neoplasmer i huvud och hals
- Nasofaryngeala sjukdomar
- Faryngeala sjukdomar
- Stomatogena sjukdomar
- Otorhinolaryngologiska sjukdomar
- Nasofaryngeala neoplasmer
- Carcinom
- Nasofaryngealt karcinom
Andra studie-ID-nummer
- 9361700387
- NHRI-EX94-9419BI
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Nasofaryngealt karcinom
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeOral Cavity Carcinom | Oral intraepitelial neoplasiFörenta staterna
-
Endo PharmaceuticalsAvslutad
-
Indira Gandhi Medical College, ShimlaOkänd
-
Washington University School of MedicineAvslutad
-
Stanford UniversityAvslutad
-
BayerAmgenAvslutadCarcinomFörenta staterna
-
Centre Leon BerardAvslutad
-
Ontario Clinical Oncology Group (OCOG)Avslutad
-
Yueyong XiaoOkänd